# Prevention of Acute Kidney Injury by N-Acetylcystein in Patients Undergone Cardiac Valve Replacement

Study · id `cardio:ct-nct03440268` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03440268](<https://clinicaltrials.gov/study/NCT03440268>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03440268

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 154 participants.

## Technical summary

Registry record NCT03440268. Randomized; double masking; primary purpose prevention. Start 2018-03-15 (anticipated); primary completion 2019-03-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 154 participants (planned count; ClinicalTrials.gov record NCT03440268, source copy `cardio:ctgov-nct03440268-2018-03-05`, retrieved 2026-10-26)
- Planned start: 2018-03-15 (anticipated) (ClinicalTrials.gov record NCT03440268, source copy `cardio:ctgov-nct03440268-2018-03-05`, retrieved 2026-10-26)
- Primary completion: 2019-03-15 (anticipated) (ClinicalTrials.gov record NCT03440268, source copy `cardio:ctgov-nct03440268-2018-03-05`, retrieved 2026-10-26)
- Completion: 2020-03-15 (anticipated) (ClinicalTrials.gov record NCT03440268, source copy `cardio:ctgov-nct03440268-2018-03-05`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT03440268, source copy `cardio:ctgov-nct03440268-2018-03-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03440268-2018-03-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Prevention of Acute Kidney Injury by N-Acetylcystein in Patients Undergone Cardiac Valve Replacement
- Condition: Surgery--Complications
- Condition: Cardiac Valve Disease
- Condition: Acute Kidney Injury
- Condition: Oxygen Radical Damage
- Condition: Post-Op Complication
- Intervention (Drug): N Acetyl Cysteine
- Intervention (Drug): Placebos
- Lead sponsor: University of Sao Paulo General Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: University of Sao Paulo General Hospital (`cardio:org-university-of-sao-paulo-general-hospital`)

## Provenance

Content hash: 3a1e3a52b8864939fa64dcc242ebf934acb0da06fbf3f8a4f2e612cee6dc06c4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
